BIONTECH SE-ADR (BNTX:NASDAQ)
$90.56 1.02 (1.1392%)
Analysed BIONTECH SE-ADR (BNTX:NASDAQ) News Sources
BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says
27-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
28-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
29-05-2026
yahoo.com
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
30-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
01-06-2026
yahoo.com
Sector Update: Healthcare Stocks Higher Late Afternoon
03-06-2026
yahoo.com
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals
08-06-2026
yahoo.com
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
09-06-2026
yahoo.com
European Equities Traded in US as ADRs Rise in Thursday Trading
11-06-2026
yahoo.com
Is BioNTech SE (BNTX) A Good Stock To Buy Now?
11-06-2026
yahoo.com
What is the current price of BIONTECH SE-ADR (BNTX:NASDAQ)?
The current price of BIONTECH SE-ADR (BNTX:NASDAQ) is $90.56.
BIONTECH SE-ADR (BNTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIONTECH SE-ADR (BNTX:NASDAQ) since the previous trading day is $1.02.
BIONTECH SE-ADR (BNTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIONTECH SE-ADR (BNTX:NASDAQ) since the previous trading day is 1.1392%.
What is the most recent average sentiment score for BIONTECH SE-ADR (BNTX:NASDAQ)?
The most recent average sentiment score for BIONTECH SE-ADR (BNTX:NASDAQ) is 61 out of 100.
What is the most recent average sentiment for BIONTECH SE-ADR (BNTX:NASDAQ)?
The most recent sentiment for BIONTECH SE-ADR (BNTX:NASDAQ) is .
SEC-8K** Filing Available For BIONTECH SE-ADR (BNTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.